Skip to content

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07095114
Enrollment
30
Registered
2025-07-31
Start date
2025-08-18
Completion date
2026-08-08
Last updated
2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ductal Carcinoma in Situ, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer

Brief summary

The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are: * Is the Magic Ink as safe as standard tattoo ink * Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.

Interventions

OTHERMagic Ink

A novel ink that is only visible when exposed to Ultraviolet light and can be hidden using white light will be inserted into the dermis to tattoo a radiation guidance tattoo into the skin of the participant

Sponsors

Barbara Ann Karmanos Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery * Participants must be 18 years of age or older * Participant must be able to understand a written informed consent document and be willing to sign it * Participant must be assigned female at birth * Participant must have a Karnofsky performance score of greater than or equal to 70% * Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following: * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation * Agree to practice true abstinence from sexual intercourse * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship) * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception. * For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6

Exclusion criteria

* Participants who have received prior radiation treatment to the affected breast. * Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink * Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study * Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued * Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.

Design outcomes

Primary

MeasureTime frameDescription
Safety of Magic Ink3 months after completion of Radiation TherapyNumber of participants with treatment related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)

Secondary

MeasureTime frameDescription
Efficacy of Magic Ink3 months after the completion of Radiation TherapyEase of radiation treatment (RT) setup. Participants will be categorized as difficult or easy setups. Difficult setups are setups with greater than 15% of the films for the treatment course result in a physician flag or reimaging based on clinically unacceptable or borderline acceptable setup.
Body Image Score3 months after the completion of Radiation TherapyParticipants will complete a Body Image survey at baseline (prior to treatment) and 3 months after the completion of radiation therapy. The body image scale survey is a 10 question Likert scale where participants give a rating of Not at all, A little, Quite a bit or Very much. Responses will be compared to historical controls

Countries

United States

Contacts

Primary ContactMichael Dominello, DO
Mdominel@med.wayne.edu3135769546

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026